NDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
TORADOL (ketorolac tromethamine) by Roche is clinical pharmacology pharmacodynamics ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits analgesic activity in animal models. First approved in 1991.
Drug data last refreshed 12h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORADOL (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) that provides rapid analgesia through prostaglandin synthetase inhibition. It is used for short-term management of moderate to severe acute pain across multiple routes (oral, intramuscular, intravenous). The S-enantiomer is responsible for analgesic activity, with peak effects occurring within 2–3 hours.
LOE Approaching
Product is in late maturity with approaching loss of exclusivity, suggesting contracting team size and focus on brand defense or managed decline strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin…
Worked on TORADOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.